Sodium-Glucose Cotransporter-2 Inhibitors: An Old Medication With New Indication in Heart Failure With Preserved Ejection Fraction

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are used for glycemic control in patients with type 2 diabetes mellitus. Recent randomized controlled trials have shown that SGLT2 inhibitors are effective treatments for heart failure (HF), regardless of left ventricular ejection fraction. This report highlights a new indication for SGLT2 inhibitors in managing HF with preserved ejection fraction and the proposed mecha- nisms of action. Data from randomized controlled trials demonstrated that SGLT2 inhibitors reduce mortality, decrease hospitalization, and enhance functional status in patients with HF with preserved ejection fraction. Current evidence recommends that nurse practitioners initiate SGLT2 inhibitors before confirming left ventricular ejection fraction in patients with suspected HF.& COPY; 2023 Elsevier Inc. All rights reserved.